Trial Parameters
Condition Autoimmunity
Sponsor Abramson Cancer Center at Penn Medicine
Study Type OBSERVATIONAL
Phase N/A
Enrollment 600
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-02-24
Completion 2026-06-30
All Conditions
Brief Summary
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Eligibility Criteria
Inclusion Criteria: * A diagnosis of cancer and prescription for a checkpoint inhibitor Exclusion Criteria: * Any subjects not willing or able to give consent * Children under the age of 18 * A history of transplant